Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Blood|July 29, 2025
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AMLRithin Nedumannil, Michael Ashby, James P Rowland, et al.
Leukemia|August 29, 2022
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposureMonika M Kutyna, Chung Hoow Kok, Yoon Lim, et al.
Bone Marrow Transplantation|April 3, 2023
Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter studyAnmol Baranwal, Rakchha Chhetri, David Yeung, et al.
Haematologica|October 7, 2017
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndromeDeepak Singhal, Monika M Kutyna, Rakchha Chhetri, et al.
American Journal of Hematology|March 2, 2017
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patientsDevendra K Hiwase, Deepak Singhal, Corinna Strupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
Pathology|September 17, 2011
Mobilisation strategies for normal and malignant cellsL Bik To, Jean-Pierre Levesque, Kirsten E Herbert, et al.
BMJ Open|January 18, 2024
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trialsZoe McQuilten, Stephane Heritier, Lucy Fox, et al.
Best Practice & Research. Clinical Haematology|December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes RegistryLucy C Fox, Zoe K McQuilten, Frank Firkin, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Pageof 5